Eckert & Ziegler Records Solid Half-Year Results

The main reason for the relatively steady performance was the continued strong growth, compared to the previous year, in sales and earnings from radiopharmaceutical products and services in the Medical segment. While laboratory equipment and brachytherapy sources, including iodine implants, suffered considerably from reduced orders from hospitals due to the coronavirus crisis, half-year sales of pharmaceutical radioisotopes increased by more than € 4 million, or almost 30%, to just under € 20 million.

In contrast, the Isotope Products segment, due to Corona, could not maintain the high sales level of the same period of the previous year and achieved sales of EUR 47.1 million, which is EUR 8.3 million or about 15% lower than in the first half of 2019. Declining revenues particularly affected the lucrative components for industrial measurement technology, the Brazilian business and waste management services. Slight increases were only recorded in medical devices components and raw materials trading.

With the figures for the first half of the year, the Eckert & Ziegler Group has largely met, and in the case of net profit for the period, even exceeded the budget targets for the current financial year, as revised due to the coronavirus crisis.

Taking into account one-off effects and the expectation that the impact of the corona pandemic will not change dramatically, the Executive Board expects revenues of EUR 170 million and a net income of at least EUR 20 million to be achieved in the FY 2020.

The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz220e.pdf